Biogen and Eisai’s Alzheimer’s drug secures support in closely watched AdCom
Pharmaceutical Technology
JUNE 12, 2023
A US Food and Drug Administration (FDA) Advisory Committee (AdCom) has unanimously voted in support of Eisai and Biogen’s Leqembi and its clinical benefit in patients with early Alzheimer’s disease , raising the drug’s full approval prospects. Notably, an FDA AdCom voted largely against Aduhelm in November 2020.
Let's personalize your content